How to preserve residual renal function among patients on peritoneal dialysis
Article Sidebar
Main Article Content
Abstract
Residual renal function is of paramount importance among patients on chronic peritoneal dialysis treatment because it has been associated with several clinical benefits, particularly a lower mortality rate. In the last decades, conventional strategies to preserve residual renal function have been widely implemented, including but not limited to optimizing volume status, controlling blood pressure and using drugs to inhibit the renin–angiotensin system. Recently, evidence has emerged supporting the roles of biocompatible low glucose degradation products solutions, icodextrin, different peritoneal dialysis techniques, diuretic use, and low protein diet with ketoacid supplement on residual renal function preservation. Nevertheless, from the currently available information, we remain uncertain whether the aforementioned tactics can halt kidney function decline. Further large scale randomized controlled studies are needed to confirm the beneficial effects of these strategies on residual renal function. In this review, we summarized current evidence regarding each technique concerning residual renal function preservation among
patients with chronic peritoneal dialysis. We hope that health care providers would understand the pivotal roles of residual renal function preservation, and be able to apply knowledge to improve patient care and outcomes.
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
This article is published under CC BY-NC-ND 4.0 license, which allows for non-commercial reuse of the published paper as long as the published paper is fully attributed. Anyone can share (copy and redistribute) the material in any medium or format without having to ask permission from the author or the Nephrology Society of Thailand.
References
Marron B, Remon C, Perez-Fontan M, Quiros P, Ortiz A. Benefits of preserving residual renal function in peritoneal dialysis. Kidney Int Suppl. 2008(108):S42-51.
Jansen MA, Hart AA, Korevaar JC, Dekker FW, Boeschoten EW, Krediet RT, et al. Predictors of the rate of decline of residual renal function in incident dialysis patients. Kidney Int. 2002;62(3):1046-53.
Tian N, Guo Q, Zhou Q, Cao P, Hong L, Chen M, et al. The Impact of Fluid Overload and Variation on Residual Renal Function in Peritoneal Dialysis Patient. PLoS One. 2016;11(4):e0153115.
Oh KH, Baek SH, Joo KW, Kim DK, Kim YS, Kim S, et al. Does Routine Bioimpedance-Guided Fluid Management Provide Additional Benefit to Non-Anuric Peritoneal Dialysis Patients? Results from COMPASS Clinical Trial. Perit Dial Int. 2018;38(2):131-8.
Justo P, Sanz AB, Egido J, Ortiz A. 3,4-Dideoxyglu-cosone-3-ene induces apoptosis in renal tubular epithelial cells. Diabetes. 2005;54(8):2424-9.
Williams JD, Topley N, Craig KJ, Mackenzie RK, Pischetsrieder M, Lage C, et al. The Euro-Balance Trial: the effect of a new biocompatible peritoneal dialysis fluid (balance) on the peritoneal membrane. Kidney Int. 2004;66(1):408-18.
Johnson DW, Brown FG, Clarke M, Boudville N, Elias TJ, Foo MW, et al. Effects of biocompatible versus standard fluid on peritoneal dialysis outcomes. J Am Soc Nephrol. 2012;23(6):1097-107.
Htay H, Johnson DW, Wiggins KJ, Badve SV, Craig JC, Strippoli GF, et al. Biocompatible dialysis fluids for peritoneal dialysis. Cochrane Database Syst Rev. 2018;10:CD007554.
Shin GT, Kim SJ, Ma KA, Kim HS, Kim D. ACE inhibitors attenuate expression of renal transforming growth factor-beta1 in humans. Am J Kidney Dis. 2000;36(5):894-902.
Li PK, Chow KM, Wong TY, Leung CB, Szeto CC. Effects of an angiotensin-converting enzyme inhibitor on residual renal function in patients receiving peritoneal dialysis. A randomized, controlled study. Ann Intern Med. 2003;139(2):105-12.
Suzuki H, Kanno Y, Sugahara S, Okada H, Nakamoto H. Effects of an angiotensin II receptor blocker, valsartan, on residual renal function in patients on CAPD. Am J Kidney Dis. 2004;43(6):1056-64.
Zhang L, Zeng X, Fu P, Wu HM. Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers for preserving residual kidney function in peritoneal dialysis patients. Cochrane Database Syst Rev. 2014(6):CD009120.
Htay H, Cho Y, Pascoe EM, Darssan D, Hawley C, Johnson DW, et al. Predictors of Residual Renal Function Decline in Peritoneal Dialysis Patients: The balANZ Trial. Perit Dial Int. 2017;37(3):283-9.
Wang AY, Brimble KS, Brunier G, Holt SG, Jha V, Johnson DW, et al. ISPD Cardiovascular and Metabolic Guidelines in Adult Peritoneal Dialysis Patients Part II - Management of Various Cardiovascular Complications. Perit Dial Int. 2015;35(4):388-96.
Jiang N, Qian J, Sun W, Lin A, Cao L, Wang Q, et al. Better preservation of residual renal function in peritoneal dialysis patients treated with a low-protein diet supplemented with keto acids: a prospective, randomized trial. Nephrol Dial Transplant. 2009;24(8):2551-8.
Medcalf JF, Harris KP, Walls J. Role of diuretics in the preservation of residual renal function in patients on continuous ambulatory peritoneal dialysis. Kidney Int. 2001;59(3):1128-33.
Kraut JA, Madias NE. Adverse Effects of the Metabolic Acidosis of Chronic Kidney Disease. Adv Chronic Kidney Dis. 2017;24(5):289-97.
Navaneethan SD, Shao J, Buysse J, Bushinsky DA. Effects of Treatment of Metabolic Acidosis in CKD: A Systematic Review and Meta-Analysis. Clin J Am Soc Nephrol. 2019;14(7):1011-20.
Chang TI, Kang EW, Kim HW, Ryu GW, Park CH, Park JT, et al. Low Serum Bicarbonate Predicts Residual Renal Function Loss in Peritoneal Dialysis Patients. Medicine (Baltimore). 2015;94(31):e1276.
Liu XY, Gao XM, Zhang N, Chen R, Wu F, Tao XC, et al. Oral Bicarbonate Slows Decline of Residual Renal Function in Peritoneal Dialysis Patients. Kidney Blood Press Res. 2017;42(3):565-74.
Michels WM, Verduijn M, Grootendorst DC, le Cessie S, Boeschoten EW, Dekker FW, et al. Decline in residual renal function in automated compared with continuous ambulatory peritoneal dialysis. Clin J Am Soc Nephrol. 2011;6(3):537-42.
Lee Y, Chung SW, Park S, Ryu H, Lee H, Kim DK, et al. Incremental Peritoneal Dialysis May be Beneficial for Preserving Residual Renal Function Compared to Full-dose Peritoneal Dialysis. Sci Rep. 2019;9(1):10105.
Feldman L, Shani M, Efrati S, Beberashvili I, Yakov-Hai I, Abramov E, et al. N-acetylcysteine improves residual renal function in peritoneal dialysis patients: a pilot study. Perit Dial Int. 2011;31(5):545-50.
Nongnuch A, Assanatham M, Panorchan K, Davenport A. Strategies for preserving residual renal function in peritoneal dialysis patients. Clin Kidney J. 2015;8(2): 202-11.